{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:40:00Z","timestamp":1769607600627,"version":"3.49.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/501100009708","name":"NOVO NORDISK FONDEN","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]},{"name":"SysKID (Systems Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment)"},{"name":"HoMAGE (Heart-omics in Aging)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in patients with diabetes. Prior studies have shown large between-patient variability in albuminuria treatment response. We previously developed and validated a urinary proteomic classifier that predicts onset and progression of chronic kidney disease. Here, we tested whether the proteomic classifier based on 273 urinary peptides (CKD273) predicts albuminuria response to spironolactone treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a post hoc analysis in a double-blind randomized clinical trial with allocation to either spironolactone 12.5\u201350\u2009mg\/day (n\u2009=\u200957) or placebo (n\u2009=\u200954) for 16 weeks. Patients were diagnosed with type 2 diabetes and resistant hypertension. Treatment was an adjunct to renin\u2013angiotensin system inhibition. Primary endpoint was the percentage change in urine albumin to creatinine ratio (UACR). Capillary electrophoresis mass spectrometry was used to quantify urinary peptides at baseline. The previously validated combination of 273 known urinary peptides was used as proteomic classifier.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Spironolactone reduced UACR relative to placebo by 50%, although with a large between-patient variability in UACR response (5th to 95th percentile, 7 to 312%). An interaction was detected between CKD273 and treatment assignment (\u03b2\u2009=\u2009\u22121.09, P\u2009=\u20090.026). Higher values of CKD273 at baseline were associated with a larger reduction in UACR in the spironolactone group (\u03b2\u2009=\u2009\u22120.70, P\u2009=\u20090.049), but not in the placebo group (\u03b2\u2009=\u20090.39, P\u2009=\u20090.25). Stratified in tertiles of baseline CKD273, reduction in UACR was greater in the highest tertile, 63% (95% confidence interval: 35\u201379%), as compared with the two other tertiles combined, 16% (\u221217 to 40%) (P\u2009=\u20090.011).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A urinary proteomics classifier can be used to identify individuals with type 2 diabetes who are more likely to show an albuminuria-lowering response to spironolactone treatment. These results suggest that urinary proteomics may be a valuable tool to tailor therapy, but confirmation in a larger clinical trial is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfw406","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T07:06:33Z","timestamp":1477465593000},"page":"296-303","source":"Crossref","is-referenced-by-count":13,"title":["Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension"],"prefix":"10.1093","volume":"33","author":[{"given":"Morten","family":"Lindhardt","sequence":"first","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Persson","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Oxlund","sequence":"additional","affiliation":[{"name":"University of Southern Denmark, Research Unit for Cardiovascular and renal protection, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ib A","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"University of Southern Denmark, Research Unit for Cardiovascular and renal protection, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Z\u00fcrbig","sequence":"additional","affiliation":[{"name":"Mosaiques Diagnostics, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Mischak","sequence":"additional","affiliation":[{"name":"Mosaiques Diagnostics, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Faculty of Heath, University of Aarhus, Aarhus, Denmark"},{"name":"The Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,1,7]]},"reference":[{"key":"2025102312484447500_gfw406-B1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312484447500_gfw406-B2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ndt\/gfs429","article-title":"Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases","volume":"28","author":"Morales","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312484447500_gfw406-B3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","article-title":"Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial","volume":"56","author":"Saklayen","year":"2008","journal-title":"J Investig Med"},{"key":"2025102312484447500_gfw406-B4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/2047487313510678","article-title":"The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial","volume":"21","author":"Heerspink","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"2025102312484447500_gfw406-B5","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"2025102312484447500_gfw406-B6","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"2025102312484447500_gfw406-B7","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1074\/mcp.M110.001917","article-title":"Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease","volume":"9","author":"Good","year":"2010","journal-title":"Mol Cell Proteomics"},{"key":"2025102312484447500_gfw406-B8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/prca.200780166","article-title":"The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy","volume":"2","author":"Rossing","year":"2008","journal-title":"Proteomics Clin Appl"},{"key":"2025102312484447500_gfw406-B9","doi-asserted-by":"crossref","first-page":"e62837","DOI":"10.1371\/journal.pone.0062837","article-title":"CKD273, a new proteomics classifier assessing CKD and its prognosis","volume":"8","author":"Argiles","year":"2013","journal-title":"PloS One"},{"key":"2025102312484447500_gfw406-B10","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1681\/ASN.2014050423","article-title":"Diagnosis and prediction of CKD progression by assessment of urinary peptides","volume":"26","author":"Schanstra","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025102312484447500_gfw406-B11","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.2337\/db12-0348","article-title":"Urinary proteomics for early diagnosis in diabetic nephropathy","volume":"61","author":"Zurbig","year":"2012","journal-title":"Diabetes"},{"key":"2025102312484447500_gfw406-B12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1755-1536-7-4","article-title":"The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?","volume":"7","author":"Genovese","year":"2014","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2025102312484447500_gfw406-B13","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1681\/ASN.2004090804","article-title":"Regression of existing glomerulosclerosis by inhibition of aldosterone","volume":"16","author":"Aldigier","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2025102312484447500_gfw406-B14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/jhh.2014.27","article-title":"Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension","volume":"29","author":"Oxlund","year":"2015","journal-title":"J Hum Hypertens"},{"key":"2025102312484447500_gfw406-B15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/mas.20051","article-title":"Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery","volume":"24","author":"Kolch","year":"2005","journal-title":"Mass Spectrom Rev"},{"key":"2025102312484447500_gfw406-B16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(06)70584-8","article-title":"Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis","volume":"7","author":"Theodorescu","year":"2006","journal-title":"Lancet Oncol"},{"key":"2025102312484447500_gfw406-B17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/pr800401m","article-title":"Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease","volume":"8","author":"Jantos-Siwy","year":"2009","journal-title":"J Proteome Res"},{"key":"2025102312484447500_gfw406-B18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/1471-2105-11-594","article-title":"Addressing the challenge of defining valid proteomic biomarkers and classifiers","volume":"11","author":"Dakna","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"2025102312484447500_gfw406-B19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0021-9673(03)00713-1","article-title":"Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers","volume":"1013","author":"Wittke","year":"2003","journal-title":"J Chromatogr A"},{"key":"2025102312484447500_gfw406-B20","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/ndt\/gfh470","article-title":"Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria","volume":"19","author":"Gaede","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312484447500_gfw406-B21","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.2337\/dc11-0324","article-title":"initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial","volume":"34","author":"Hellemons","year":"2011","journal-title":"Diabetes Care"},{"key":"2025102312484447500_gfw406-B22","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2014070688","article-title":"Reducing albuminuria as surrogate endpoint c. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis","volume":"26","author":"Heerspink","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025102312484447500_gfw406-B23","first-page":"1866","article-title":"Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-protect 2 study","volume-title":"Nephrol Dial Transplant","author":"Lindhardt","year":"2017"},{"key":"2025102312484447500_gfw406-B24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrneph.2012.217","article-title":"Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy","volume":"8","author":"Roscioni","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2025102312484447500_gfw406-B25","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/ndt\/gfu039","article-title":"Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy","volume":"29","author":"Siwy","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312484447500_gfw406-B26","doi-asserted-by":"crossref","first-page":"e010310","DOI":"10.1136\/bmjopen-2015-010310","article-title":"Proteomic prediction and renin angiotensin aldosterone system inhibition prevention of early diabetic nephropathy in type 2 diabetic patients with normoalbuminuria (PRIORITY): Essential study design and rationale of a randomised clinical multicentre trial","volume":"6","author":"Lindhardt","year":"2016","journal-title":"BMJ Open"},{"key":"2025102312484447500_gfw406-B27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00285287","article-title":"Albuminuria reflects widespread vascular damage. The Steno hypothesis","volume":"32","author":"Deckert","year":"1989","journal-title":"Diabetologia"},{"key":"2025102312484447500_gfw406-B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2014.10.014","article-title":"Microalbuminuria: a parameter that has changed diabetes care","volume":"107","author":"Parving","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"2025102312484447500_gfw406-B29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2025102312484447500_gfw406-B30","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"2025102312484447500_gfw406-B31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/dom.12600","article-title":"Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2025102312484447500_gfw406-B32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s001250050140","article-title":"Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment","volume":"37","author":"Rossing","year":"1994","journal-title":"Diabetologia"},{"key":"2025102312484447500_gfw406-B33","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00125-014-3330-9","article-title":"Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies","volume":"57","author":"Schmieder","year":"2014","journal-title":"Diabetologia"},{"key":"2025102312484447500_gfw406-B34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2025102312484447500_gfw406-B35","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"key":"2025102312484447500_gfw406-B36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ndt\/gfm710","article-title":"Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagen-N-peptidase in hypertension-induced renal damage","volume":"23","author":"Hultstrom","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312484447500_gfw406-B37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ki.2010.154","article-title":"A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy","volume":"78","author":"Pang","year":"2010","journal-title":"Kidney Int"},{"key":"2025102312484447500_gfw406-B38","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2337\/db06-1662","article-title":"Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy","volume":"56","author":"Westermann","year":"2007","journal-title":"Diabetes"},{"key":"2025102312484447500_gfw406-B39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2369-11-29","article-title":"Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria","volume":"11","author":"Andersen","year":"2010","journal-title":"BMC Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/33\/2\/296\/23748614\/gfw406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/33\/2\/296\/23748614\/gfw406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:49:16Z","timestamp":1761238156000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/33\/2\/296\/2864903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,7]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,1,7]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw406","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2017,1,7]]}}}